Neoadjuvant Pepinemab Primes Tumor Immunity | Docwire News
This was an unexpected finding because mature TLS are typically rare in poorly immunogenic HPV-negative HNSCC.
This was an unexpected finding because mature TLS are typically rare in poorly immunogenic HPV-negative HNSCC.
Sign up for DocWire News eNewsletters to get the latest medical industry news and expert insights and to join an extensive community of health care…
An interim analysis of the COMPLETE study found that pegcetacoplan improved indicators of blood health in patients with paroxysmal nocturnal hemoglobinuria.
Pegcetacoplan was found to reduce proteinuria and stabilize eGFR in adolescent patients with C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis.
The study data presented at EHA2025 were from patients who had disease resistant to prior therapy or intolerance to therapy.
Treatment effects of nefecon were consistent independent of baseline estimated glomerular filtration rate (eGFR) among patients with IgA nephropathy (IgAN).
In a cohort of adults and adolescents marstacimab produced bleed control superior to that from on-demand bypassing agent.
An analysis confirmed the efficacy and safety of pegcetacoplan for patients with C3 glomerulopathy and primary immune complex membranoproliferative and nephrotic range proteinuria.
The results are reported from an international cohort and support adding the agent to plasma exchange and immunosuppression.
Researchers identified three immune phenotypes of checkpoint inhibitor-induced acute interstitial nephritis (ICI-AIN) with differing clinicobiological presentations and outcomes.
The agent notably in preclinical studies has accomplished increased HbF without any evident cytotoxicity.